Treatment for augmenting parasympathetic activity and reducing HR, such as with acetylcholinesterase inhibitors, may potentially improve glycemic control and cardiovascular outcomes in patients with AIS and type 2 diabetes mellitus. The gene discussed is ACHE; the disease is diabetes mellitus.